NASDAQ:MACK - Merrimack Pharmaceuticals Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$5.30 -0.03 (-0.56 %)
(As of 07/16/2018 04:00 PM ET)
Previous Close$5.33
Today's Range$5.17 - $5.38
52-Week Range$4.71 - $15.40
Volume112,000 shs
Average Volume185,650 shs
Market Capitalization$71.12 million
P/E RatioN/A
Dividend YieldN/A
Beta1.98
Merrimack Pharmaceuticals logoMerrimack Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on biomarker-defined cancers in the United States. The company's clinical programs include MM-121, which is in Phase II clinical trial for the treatment of patients with heregulin positive non-small cell lung cancer; and MM-141, a human tetravalent bispecific antibody that is in Phase II clinical trial for treating patients with metastatic pancreatic cancer with high serum levels of free insulin-like growth factor 1. Its clinical program also comprises MM-310, an antibody-directed nanotherapeutic, which is in Phase I clinical trial to solid tumors. In addition, the company is developing preclinical product candidates for various solid tumor indications. Merrimack Pharmaceuticals, Inc. was incorporated in 1993 and is headquartered in Cambridge, Massachusetts.

Receive MACK News and Ratings via Email

Sign-up to receive the latest news and ratings for MACK and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:MACK
CUSIP59032810
Phone617-441-1000

Debt

Debt-to-Equity RatioN/A
Current Ratio4.40
Quick Ratio4.40

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$144.27 million
Price / Sales0.49
Cash FlowN/A
Price / CashN/A
Book Value$7.22 per share
Price / Book0.73

Profitability

EPS (Most Recent Fiscal Year)($5.66)
Net Income$472.02 million
Net MarginsN/A
Return on Equity-64.89%
Return on Assets-40.80%

Miscellaneous

Employees72
Outstanding Shares13,340,000
Market Cap$71.12

The Truth About Cryptocurrencies

Merrimack Pharmaceuticals (NASDAQ:MACK) Frequently Asked Questions

What is Merrimack Pharmaceuticals' stock symbol?

Merrimack Pharmaceuticals trades on the NASDAQ under the ticker symbol "MACK."

When did Merrimack Pharmaceuticals' stock split? How did Merrimack Pharmaceuticals' stock split work?

Merrimack Pharmaceuticals shares reverse split before market open on Wednesday, September 6th 2017. The 1-10 reverse split was announced on Thursday, August 31st 2017. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, September 5th 2017. An investor that had 100 shares of Merrimack Pharmaceuticals stock prior to the reverse split would have 10 shares after the split.

How were Merrimack Pharmaceuticals' earnings last quarter?

Merrimack Pharmaceuticals Inc (NASDAQ:MACK) posted its quarterly earnings results on Tuesday, May, 8th. The biopharmaceutical company reported ($1.33) EPS for the quarter, missing the consensus estimate of ($1.28) by $0.05. View Merrimack Pharmaceuticals' Earnings History.

When is Merrimack Pharmaceuticals' next earnings date?

Merrimack Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, August, 7th 2018. View Earnings Estimates for Merrimack Pharmaceuticals.

What price target have analysts set for MACK?

2 brokerages have issued 1 year price objectives for Merrimack Pharmaceuticals' stock. Their forecasts range from $7.00 to $7.00. On average, they expect Merrimack Pharmaceuticals' share price to reach $7.00 in the next year. This suggests a possible upside of 32.1% from the stock's current price. View Analyst Ratings for Merrimack Pharmaceuticals.

What is the consensus analysts' recommendation for Merrimack Pharmaceuticals?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Merrimack Pharmaceuticals in the last year. There are currently 1 sell rating and 1 hold rating for the stock, resulting in a consensus recommendation of "Hold."

Are investors shorting Merrimack Pharmaceuticals?

Merrimack Pharmaceuticals saw a decrease in short interest in the month of June. As of June 29th, there was short interest totalling 949,567 shares, a decrease of 34.7% from the June 15th total of 1,453,304 shares. Based on an average daily volume of 708,077 shares, the days-to-cover ratio is presently 1.3 days. Approximately 7.4% of the company's shares are sold short. View Merrimack Pharmaceuticals' Current Options Chain.

Who are some of Merrimack Pharmaceuticals' key competitors?

Who are Merrimack Pharmaceuticals' key executives?

Merrimack Pharmaceuticals' management team includes the folowing people:
  • Dr. Richard Peters, Pres, CEO & Director (Age 55)
  • Ms. Jean M. Franchi, CFO & Treasurer (Age 52)
  • Mr. Jeffrey A. Munsie, Gen. Counsel, Head of Corp. Operations & Sec. (Age 41)
  • Dr. Daryl C. Drummond Ph.D., Head of Research (Age 49)
  • Dr. Sergio L. Santillana, Chief Medical Officer (Age 55)

Has Merrimack Pharmaceuticals been receiving favorable news coverage?

Press coverage about MACK stock has been trending somewhat negative recently, according to Accern. The research firm ranks the sentiment of news coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Merrimack Pharmaceuticals earned a media sentiment score of 0.00 on Accern's scale. They also assigned news articles about the biopharmaceutical company an impact score of 44.27 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company's share price in the next several days.

Who are Merrimack Pharmaceuticals' major shareholders?

Merrimack Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional shareholders include FMR LLC (4.51%). Company insiders that own Merrimack Pharmaceuticals stock include Birgit M Schoeberl, Daryl C Drummond and Ulrik B Nielsen. View Institutional Ownership Trends for Merrimack Pharmaceuticals.

How do I buy shares of Merrimack Pharmaceuticals?

Shares of MACK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Merrimack Pharmaceuticals' stock price today?

One share of MACK stock can currently be purchased for approximately $5.30.

How big of a company is Merrimack Pharmaceuticals?

Merrimack Pharmaceuticals has a market capitalization of $71.12 million and generates $144.27 million in revenue each year. The biopharmaceutical company earns $472.02 million in net income (profit) each year or ($5.66) on an earnings per share basis. Merrimack Pharmaceuticals employs 72 workers across the globe.

How can I contact Merrimack Pharmaceuticals?

Merrimack Pharmaceuticals' mailing address is ONE KENDALL SQUARE SUITE B7201, CAMBRIDGE MA, 02139. The biopharmaceutical company can be reached via phone at 617-441-1000 or via email at [email protected]


MarketBeat Community Rating for Merrimack Pharmaceuticals (NASDAQ MACK)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  281 (Vote Outperform)
Underperform Votes:  210 (Vote Underperform)
Total Votes:  491
MarketBeat's community ratings are surveys of what our community members think about Merrimack Pharmaceuticals and other stocks. Vote "Outperform" if you believe MACK will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MACK will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 7/16/2018 by MarketBeat.com Staff

Featured Article: How Short Selling Works

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.